**INTRAPERITONEAL INOCULATION (Yale)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Intraperitoneal | 108 | 3 | 3/3 | 5,5,6 | **<100leptospires** |
| 1000 | 3 | 3/3 | 7,8,8 |
| 100 | 3 | 3/3 | 9,9,9 |
| 2 | Intraperitoneal | 100 | 4 | 4/4 | 11,11,11,11 | **<10leptospires** |
| 10 | 4 | 4/4 | 10,10,10,12 |
| 3 | Intraperitoneal | 100 | 4 | 4/4 | 8,9,9,9 | **<10leptospires** |
| 10 | 4 | 3/4 | 8,8,9,- |

**INTRAPERITONEAL INOCULATION (Brazil)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Intraperitoneal | 103 | 4 | 4/4 | 9,9,10,11 | **<10leptospires** |
| 250 | 4 | 4/4 | 9,9,10,10 |
| 102 | 4 | 4/4 | 9,10,10,12 |
| 50 | 4 | 4/4 | 10,12,12,12 |
| 10 | 4 | 4/4 | 11,12,13,13 |
| 2 | Intraperitoneal | 104 | 4 | 4/4 | 8,9,9,10 | **<10leptospires** |
| 103 | 4 | 4/4 | 9,10,12,13 |
| 250 | 4 | 4/4 | 9,10,10,12 |
| 102 | 4 | 4/4 | 10,11,12,15 |
| 10 | 4 | 4/4 | 10,10,11,11 |
| 3 | Intraperitoneal | 104 | 4 | 4/4 | 9,10,10,10 | **10leptospires** |
| 103 | 4 | 4/4 | 10,10,10,15 |
| 250 | 4 | 4/4 | 9,10,10,10 |
| 102 | 4 | 4/4 | 12,13,13,14 |
| 10 | 4 | 2/4 | 10,12,-,- |
| 4 | Intraperitoneal | 106 | 4 | 4/4 | 6,6,7,7 | **<10leptospires** |
| 104 | 4 | 4/4 | 7,8,9,10 |
| 102 | 4 | 4/4 | 8,9,11,12 |
| 5 | Intraperitoneal | 106 | 4 | 4/4 | 6,6,7,7 | **<10leptospires** |
| 104 | 4 | 4/4 | 8,9,10,11 |
| 102 | 4 | 4/4 | 7,8,9,11 |
| 6 | Intraperitoneal | 106 | 4 | 4/4 | 6,9,9,10 | **<10leptospires** |
| 104 | 4 | 4/4 | 9,10,11,14 |
| 102 | 4 | 4/4 | 9,10,10,14 |
| 7 | Intraperitoneal | 106 | 4 | 4/4 | 6,7,8,9 | **<10leptospires** |
| 104 | 4 | 4/4 | 8,9,11,14 |
| 102 | 4 | 4/4 | 9,10,10,11 |
| 8 | Intraperitoneal | 104 | 4 | 4/4 | 8,8,8,8 | **<10leptospires** |
| 103 | 4 | 4/4 | 9,9,10,10 |
| 102 | 4 | 4/4 | 10,10,11,11 |
| 10 | 4 | 4/4 | 10,11,11,11 |

**CONJUNCTIVAL INOCULATION (Yale)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Conjunctival | 108 | 4 | 4/4 | 9,9,9,9 | **106 leptospires** |
| 107 | 4 | 4/4 | 16,16,17,17 |
| 106 | 4 | 2/4 | 17,17,-,- |
| 2 | Conjunctival | 108 | 4 | 4/4 | 7,8,11,11 | **2.15 x 106 leptospires** |
| 107 | 4 | 4/4 | 8,9,9,9 |
| 106 | 4 | 1/4 | 10,-,-,- |
| 3 | Conjunctival | 107 | 4 | 4/4 | 9,9,12,12 | **2.15 x 106 leptospires** |
| 106 | 4 | 1/4 | 10,-,-,- |
| 105 | 4 | 0/4 | -,-,-,- |
| 4 | Conjunctival | 108 | 4 | 4/4 | 10,11,11,11 | **1 x 107 leptospires** |
| 107 | 4 | 2/4 | 10,10 |
| 106 | 4 | 0/4 | -,-,-,- |
| 5 | Conjunctival | 108 | 4 | 4/4 | 8,9,9,10 | **3.16 x 107 leptospires** |
| 107 | 4 | 0/4 | -,-,-,- |
|  |  |  |  |

**CONJUNCTIVAL INOCULATION (Brazil)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Conjunctival | 106 | 4 | 3/4 | 9,9,10 | **4.64 x 105 leptospires** |
| 105 | 4 | 0/4 | -,-,-,- |
| 104 | 4 | 0/4 | -,-,-,- |
| 103 | 4 | 0/4 | -,-,-,- |
| 102 | 4 | 0/4 | -,-,-,- |
| 2 | Conjunctival | 106 | 4 | 2/4 | 11,11 | **106 leptospires** |
| 105 | 4 | 0/4 | -,-,-,- |
| 104 | 4 | 0/4 | -,-,-,- |
| 3 | Conjunctival | 108 | 4 | 4/4 | 9,9,10,12 | **<108 leptospires** |
| 4 | Conjunctival | 108 | 4 | 4/4 | 8,8,9,9 | **<108 leptospires** |
| 5 | Conjunctival | 108 | 8 | 8/8 | 8,9,9,9,9,9,9,9 | **<108 leptospires** |
| 6 | Conjunctival | 108 | 12 | 12/12 | 8,8,8,8,8,8,8,9,9,10,10,10 | **<108 leptospires** |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **INTACT SKIN (Yale)** | | | | | | |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Intact skin | 108 | 4 | 2/4 | 10,11,- - | **108 leptospires** |
| 106 | 4 | 0/4 | -,-,-,- |
| 104 | 4 | 0/4 | -,-,-,- |
| 2 | Intact skin | 108 | 4 | 0/4 | -,-,-,- | Could not be calculated as no animal died |
| 107 | 4 | 0/4 | -,-,-,- |
| 106 | 4 | 0/4 | -,-,-,- |
|  |  |  |  |  |  |  |
| **SHAVED SKIN (Yale)** | | | | | | |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Shaved skin | 108 | 4 | 3/4 | 8,9,19,- | **4.67 x 107 leptospires** |
| 106 | 4 | 0/4 | -,-,-,- |
| 104 | 4 | 0/4 | -,-,-,- |
| 2 | Shaved skin | 108 | 4 | 2/4 | 12,13,-,- | **4.28 x 106 leptospires** |
| 107 | 4 | 3/4 | 10,11,12,- |
| 106 | 4 | 2/4 | 12,13,-,- |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **SHAVED AND SCARIFIED SKIN (Yale)** | | | | | | |
| **Exp.** | **Route** | **Infection dose (leptospires)** | **n** | **Lethality** | **Days for death** | **LD50** |
| 1 | Epidermal | 1000 | 4 | 3/4 | 9,10,10,- | **316** |
| 100 | 4 | 4/4 | 11,-,-,- |
| 10 | 4 | 1/4 | -,-,-,- |
| 2 | Epidermal | 1000 | 4 | 3/4 | 10,10,20,- | **29.8** |
| 100 | 4 | 1/4 | 10,10,10,19 |
| 10 | 4 | 0/4 | 10,-,-,- |
| 3 | Epidermal | 1000 | 4 | 4/4 | 8,8,12,12 | Could not be calculated but looks like <10 leptospires |
| 100 | 4 | 3/4 | 8,8,9,- |
| 10 | 4 | 4/4 | 7,7,9,9 |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Notes from email sent 5/12/15  Dear Katie,  Here I am sending you the word document with all the LD50 experiments with intraperitoneal, conjunctival, intact skin, shaved skin and shaved and scarified skin routes. In conjunctival route of inoculation, we have used higher dose of leptospires for challenge. Same is true for intact and shaved skin.    Please take a look at the data and let us know if anything else to be done from our side.  Best regards,  Vimla |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |